> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lupin Limited ’483 Released
- URL: https://www.fdaweb.com/lupin-limited-483-released/
- Published: 2017-06-29T12:00:00.000Z
- Updated: 2026-09-14T22:32:17.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139065

FDA has published the [FDA-483](http://www.fda.gov/downloads/Drugs/GuidanceComplanceRegulatoryInformation/CDERFOIAElectronicReadingRoom/UCM565158.pdf?ref=fdaweb.com) issued following a 6/12-6/16 inspection at Lupin Limited, Madhya Pradesh, India. Observations shown in the form were: 

- failing to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed;
- failing to establish control procedures that monitor the output of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product;
- failing to take representative samples of in-process materials for determination of conformance to specifications;
- failing to maintain adequate acceptance criteria for the sampling and testing conducted by the quality control unit to assure that batches of drug products meet each appropriate specification as a condition for their approval and release; and
- failing to exercise appropriate controls over computers or related systems to assure that changes in master production and control records are instituted only by authorized personnel.